Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

The newest in­ter­im da­ta from Janux Ther­a­peu­tics’ Phase 1a prostate can­cer tri­al have dri­ven the com­pa­ny’s shares $JANX up 66% pre­mar­ket Tues­day as in­vestors mull …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER